Format

Send to

Choose Destination
Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1.

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Author information

1
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, 2525 West End Avenue, Nashville, TN, 37203, USA.
2
Department of Pharmacology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, TN, 37232, USA.
3
Points & Assists, LLC, Bala Cynwyd, PA, USA.
4
Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, TN, 37232, USA.
5
Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 465 21st Avenue South, Nashville, TN, 37232, USA.
6
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN, 37232, USA.
7
Department of Cancer Biology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN, 37232, USA.
8
Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, Nashville, TN, 37232, USA.
9
Center for Technology Transfer and Commercialization, Vanderbilt University, 1207 17th Avenue South, Nashville, TN, 37212, USA.
10
Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 465 21st Avenue South, Nashville, TN, 37232, USA. Rebecca.Cook@Vanderbilt.Edu.
11
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN, 37232, USA. Rebecca.Cook@Vanderbilt.Edu.
12
Department of Biomedical Engineering, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN, 37235, USA. Rebecca.Cook@Vanderbilt.Edu.

Abstract

Metastatic cancers impose significant burdens on patients, affecting quality of life, morbidity, and mortality. Even during remission, microscopic metastases can lurk, but few therapies directly target tumor cell metastasis. Agents that interfere with this process would represent a new paradigm in cancer management, changing the 'waiting game' into a time of active prevention. These therapies could take multiple forms based on the pathways involved in the metastatic process. For example, a phenome-wide association study showed that a single nucleotide polymorphism in the gene TBXA2R is associated with increased metastasis in multiple primary cancers (Pā€‰=ā€‰0.003), suggesting clinical applicability of TBXA2R antagonists. Emerging data related to the role of platelets in metastasis are concordant with our sense that these pathways present significant opportunities for therapeutic development. However, before real progress can be made toward clinical targeting of the metastatic process, foundational work is needed to define informative measures of critical elements such as circulating tumor cells and tumor DNA, and circulatory vs. lymphatic spread. These challenges require an expansion of team science and composition to obtain competitive funding. At our academic medical center, we have implemented a Cancer Metastasis Inhibition (CMI) program investigating this approach across multiple cancers.

PMID:
29218624
PMCID:
PMC5826865
[Available on 2019-02-01]
DOI:
10.1007/s11523-017-0542-1

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center